-
Electronic (PDF)
-
Site License
-
Enterprisewide
Urinary Incontinence - Pipeline Review, Q4 2010
Global Markets Direct, December 2010, Pages: 64
Urinary Incontinence - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “Urinary Incontinence Pipeline Review, Q4 2010”, provides an overview of the Urinary Incontinence therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. “Urinary Incontinence-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Urinary Incontinence.
- A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Urinary Incontinence pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Urinary Incontinence therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Urinary Incontinence Overview
Therapeutics Development
An Overview of Pipeline Products for Urinary Incontinence
Urinary Incontinence Therapeutics under Development by Companies
Urinary Incontinence Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Urinary Incontinence Therapeutics Development
Allergan, Inc.
Eli Lilly and Company
Daiichi Sankyo Company, Ltd
Dainippon Sumitomo Pharma Co., Ltd.
Astellas Pharma Inc.
Auxilium Pharmaceuticals, Inc.
Japan Tobacco Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Recordati S.p.A.
Teva Pharmaceutical Industries Limited
Ferring Pharmaceuticals
Addex Pharmaceuticals
Evotec Aktiengesellschaft
MediciNova, Inc.
Urigen Pharmaceuticals, Inc.
Theravance, Inc.
Orexo AB
Plethora Solutions Holdings plc
KeyNeurotek Pharmaceuticals AG
Respiratorius AB
Avera Pharmaceuticals, Inc.
Xention Limited
Celogos
FemmePharma Global Healthcare, Inc.
Mayo Clinic
Mt Cook Pharma. Inc.
Universities/Institutes Involved in Urinary Incontinence Therapeutics Development
Urinary Incontinence Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DR-3001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MINIRIN Melt - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YM178 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YM178 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YM905 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Anturol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tolterodine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Urinary Incontinence - Featured News
Jun 18, 2010: Astellas Submits MAA For Mirabegron For Treatment Of Overactive Bladder In Japan
Jun 02, 2010: Plethora Products “Showcased” at The American Urological Association Annual Meeting
Apr 29, 2010: EnzymeRx Announces Top Line Phase I Results for Pegsitacase
Apr 23, 2010: Study Shows AFREZZA Controls Blood Sugar Levels In Type 1 Diabetes
Mar 03, 2010: Antares Completes Patient Enrollment In Phase III Pivotal Trial Of Anturol
Dec 22, 2009: Astellas Submits Market Authorization Application For YM905 (Solifenacin Succinate) For The Treatment Of Overactive Bladder
Sep 30, 2009: Plethora Solutions Announces Results From Clinical Study Of PSD506 In Patients With Urinary Urge Incontinence And Benign Prostatic Hyperplasia
Sep 15, 2009: Calixa Therapeutics To Make Multiple Presentations On CXA-101 And CXA-101/Tazobactam At The 49th Annual Interscience Conference On Antimicrobial Agents And Chemotherapy
Jul 16, 2009: PSD503: Development Update
Mar 12, 2009: Xention Enters Drug Discovery Agreement with Ono Pharmaceutical Co Ltd
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
